Actively Recruiting

Phase Not Applicable
Age: 18Years +
MALE
NCT05588700

Impact of a Physical Activity Program to Reduce Long-term Cancer-related Fatigue in Metastatic Testicular Germ Cell Tumor Patients

Led by Centre Leon Berard · Updated on 2026-03-31

236

Participants Needed

12

Research Sites

678 weeks

Total Duration

On this page

Sponsors

C

Centre Leon Berard

Lead Sponsor

N

National Cancer Institute, France

Collaborating Sponsor

AI-Summary

What this Trial Is About

Testicular germ cell tumor (TGCT) is the most common malignancy in men between 15 and 40 years. Although TCGT survivors have a good survival prognosis, they suffer from short- and long-term sequelae such as chronic fatigue, psychological disorders, cardiovascular toxicities and second malignancies. The benefits of physical activity (PA) during treatments have been demonstrated in cancer patients to improve quality of life (QoL) and physical fitness and to reduce fatigue. However, few PA programs have been proposed to TGCT patients and their effects on sequelae have not been assessed yet. A growing body of evidence links treatment-related alteration in the gut microbiota to sequelae of cancer survivors, including fatigue and cardiovascular toxicities. Also, PA has been known as a possible modulator of the gut microbiota composition. To date, no study has been conducted to examine how the gut microbiota and its metabolites moderate the effect of PA on fatigue and other late effects in TGCT survivors. The objectives will be to assess the impact of a PA program on fatigue and other sequelae and to investigate how the gut microbiota and its metabolites moderate the associations between PA and sequelae. We will conduct a prospective, multicenter, phase III, randomized controlled trial of a one-year supervised PA program. 236 men with metastatic TGCT and eligible for a first line of chemotherapy will be randomly assigned to either PA intervention or control arm. All patients will benefit from a connected activity tracker and PA recommendations. In the intervention arm, PA will be based on supervised sessions and motivational interviews. The primary endpoint (fatigue) will be assessed at 3 years. The trial will provide novel insights into the impact of PA on fatigue and other sequelae in TGCT survivors with understanding a potential underlying mechanism of gut microbiota. This evidence will support the development of targeted PA guidelines to improve QoL and reduce sequelae in TGCT survivors.

CONDITIONS

Official Title

Impact of a Physical Activity Program to Reduce Long-term Cancer-related Fatigue in Metastatic Testicular Germ Cell Tumor Patients

Who Can Participate

Age: 18Years +
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Men 18 years or older
  • Diagnosed with metastatic germ cell tumor confirmed by tissue examination (seminoma or non-seminoma)
  • Planned first-line chemotherapy with BEP, EP, or VIP
  • Own a smartphone to connect with an activity tracker
  • Performance status of 2 or less
  • Medical certificate confirming ability to practice adapted physical activity
  • Willing and available to participate for the study duration
  • Able to understand, read, and write French
  • Covered by a social security plan
  • Signed informed consent form
Not Eligible

You will not qualify if you...

  • Having symptomatic bone or brain metastases
  • Central nervous system issues causing walking difficulties
  • History or coexistence of another primary cancer except certain in situ cancers, basal cell skin cancer, or cancers in complete remission over 3 years
  • Contraindications to physical activity such as uncontrolled hypertension or heart disease
  • Unable to be followed medically or socially for the study duration
  • Legally deprived of liberty or protected adults
  • Participating in another physical activity study concurrently

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 12 locations

1

Institut de Cancérologie de Lorraine

Angers, France, 49000

Not Yet Recruiting

2

CHU Jean Minjoz

Besançon, France, 25030

Not Yet Recruiting

3

Institut Bergonié

Bordeaux, France, 33000

Not Yet Recruiting

4

Centre François Baclesse

Caen, France, 14076

Not Yet Recruiting

5

Centre Oscar Lambret

Lille, France, 59020

Not Yet Recruiting

6

Centre Leon Berard

Lyon, France, 69008

Actively Recruiting

7

Institut de Cancérologie de Lorraine

Nancy, France, 54519

Actively Recruiting

8

Centre Antoine Lacassagne

Nice, France, 06189

Not Yet Recruiting

9

AP-HP Tenon

Paris, France, 75020

Not Yet Recruiting

10

Centre Eugène Marquis

Rennes, France, 35000

Not Yet Recruiting

11

CHU Tours

Tours, France, 37000

Not Yet Recruiting

12

Institut Gustave Roussy

Villejuif, France, 94800

Actively Recruiting

Loading map...

Research Team

C

Carmen Dupuis, PhD

CONTACT

O

Olivia Pérol, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here